Document:

Exhibit 10.3.2

 

Certain identified information has been excluded from the exhibit
pursuant to Item 601(a)(6) of Regulation S-K due to personal privacy concerns or pursuant to Item 601(b)(10)(iv) because it is both not
material and is the type of information that the registrant treats as private or confidential. Redacted information is indicated by: [***]

 

 

 

	July 5, 2018
	UBC File: F16-05805

 

VIA EMAIL

 

Dr. Elliot Goldstein

President and CEO

ProMis Neurosciences, Inc.

Suite 200, 1920 Yonge Street

Toronto, ON

M4S 3E2

[***]

 

Dear Dr. Goldstein,

 

	Re:	Collaborative Research Agreement between The University of British Columbia (“UBC”) and Vancouver Coastal Health Authority (“Hospital”) (UBC and Hospital collectively, the “Institution”) and ProMis Neurosciences, Inc. (the “Sponsor”) effective April 1, 2016 and amended by Amendment No. 1 dated December 13, 2017 (the “Agreement”)

Amendment No. 2

 

The Institution and Sponsor have executed the Agreement and hereby
agree to amend the Agreement as follows:

 

Article 4.1 shall be revised and read as follows: 

 

“4.1
The Parties understand and agree that, subject to Article 4.3, and excluding any intellectual property related costs under Section 7,
the total costs to the Sponsor hereunder will be $[***] (Canadian funds). The Parties acknowledge that any budget categories that may
be described in the Project are estimates only and that changes from category to category may be made at the Institution’s discretion.
The Sponsor will pay to UBC the amounts of the following due dates:

 

	 	1)	Amount already received by UBC	 	$[***]

 

	 	2)	Amount due upon signature of this Amendment No. 2	 	$[***]

 

	 	3)	August 1, 2018	 	$[***]

 

	 	4)	October 1, 2018	 	$[***]

 

	 	5)	January 1, 2019	 	$[***]

 

All other terms and conditions of the Agreement will remain in full
force and effect and will continue for the duration of the Agreement. The Agreement and this Amendment No. 2 will be read together and
constitute one agreement.

 

 

 

     

     

    

 

This Amendment to the Agreement may be signed in counterparts either
through original copies or by facsimile or electronically each of which will be deemed an original and all of which will constitute the
same instrument.

 

Sincerely,

 

/s/ Jacqueline Lee

Jacqueline Lee

Industry Grants Officer

 

     

     

    

 

SIGNED FOR AND ON BEHALF of

THE UNIVERSITY OF BRITISH COLUMBIA

by its authorized signatory:

 

_____________________

	Name:	 

	Title:	 

	Date:	 

 

 

SIGNED FOR AND ON BEHALF of

THE UNIVERSITY OF BRITISH COLUMBIA

by its authorized signatory:

 

_____________________

	Name:	 

	Title:	 

	Date:	 

 

 

SIGNED FOR AND ON BEHALF of

VANCOUVER COASTAL HEALTH AUTHORITY

by its authorized signatory:

 

_____________________

	Name:	 

	Title:	 

	Date:	 

 

 

SIGNED FOR AND ON BEHALF of

PROMIS NEUROSCIENCES, INC. 

by its authorized signatory:

/s/ Elliot Goldstein

	Name:	Dr. Elliot Goldstein, MD

	Title:	President & CEO

	Date:	July 20, 2018

 

[signature page]

     

     

    

 

Acknowledged by

 

/s/ Neil Cashman

Dr. Neil Cashman

Principal Investigator

Department of Neurology

Date:

 

 

[acknowledgement page]Exhibit 10.3.3

 

Certain identified information has been excluded from the exhibit
pursuant to Item 601(a)(6) of Regulation S-K due to personal privacy concerns or pursuant to Item 601(b)(10)(iv) because it is both not
material and is the type of information that the registrant treats as private or confidential. Redacted information is indicated by: [***]

 

 

 

	February 13, 2019	UBC File: F16-05805

 

VIA EMAIL

 

Dr. Elliot Goldstein

President and CEO

ProMis Neurosciences, Inc.

Suite 200, 1920 Yonge Street

Toronto, ON

M4S 3E2

[***]

 

 

Dear Dr. Goldstein,

 

	Re:	Collaborative Research Agreement between The University of British Columbia (“UBC”) and Vancouver Coastal Health Authority (“Hospital”) (UBC and Hospital collectively, the “Institution”) and ProMis Neurosciences, Inc, (the “Sponsor”) effective April 1, 2016 and amended by Amendment No. 1 dated December 13, 2017 and Amendment No.2 dated July 5, 2018 (the “Agreement”)

Amendment No. 3

 

 

The Institution and Sponsor have executed the Agreement and hereby
agree to amend the Agreement as follows:

 

Article 4.1 shall be revised and read as follows: 

 

“4.1
The Parties understand and agree that, subject to Article 4.3, and excluding any intellectual property related costs under Section 7,
the total costs to the Sponsor hereunder will be $[***] (Canadian funds). The Parties acknowledge that any budget categories that may
be described in the Project are estimates only and that changes from category to category may be made at the Institution’s discretion.
The Sponsor will pay to UBC the amounts of the following due dates:

 

	 	1)	Amount already received by UBC	 	$[***]

 

	 	2)	Amount due upon signature of this Amendment No. 3	 	$[***]

 

	 	3)	June 1, 2019	 	$[***]

 

	 	4)	September 1, 2019	 	$[***]

 

	 	5)	December 1, 2020	 	$[***]

 

	 	6)	March, 2020	 	$[***]

 

	 	7)	June 1, 2020	 	$125,000

 

	 	8)	September 1, 2020	 	$125,000

 

	 	9)	December 1, 2020	 	$125,000

 

All other terms and conditions
of the Agreement will remain in full force and effect and will continue for the duration of the Agreement. The Agreement and this Amendment
No. 3 will be read together and constitute one agreement.

 

 

     

     

    

 

This Amendment to the Agreement may be signed in counterparts either
through original copies or by facsimile or electronically each of which will be deemed an original and all of which will constitute the
same instrument.

 

Sincerely,

 

/s/ Jacqueline Lee

Jacqueline Lee

Industry Grants Officer

 

     

     

    

 

SIGNED FOR AND ON BEHALF of

THE UNIVERSITY OF BRITISH COLUMBIA

by its authorized signatory:

 

/s/ Mario Kasapi

	Name:	Mario Kasapi

	Title:	Associate Director, UILO

	Date:	March 6, 2019

 

 

SIGNED FOR AND ON BEHALF of

THE UNIVERSITY OF BRITISH COLUMBIA

by its authorized signatory:

/s/ J. P. Heale

	Name:	Dr. J. P. Heale

	Title:	Managing Director, UILO

	Date:	March 6, 2019

 

 

SIGNED FOR AND ON BEHALF of

VANCOUVER COASTAL HEALTH AUTHORITY

by its authorized signatory:

/s/ W. Robert McMaster

	Name:	Dr. W. Robert McMaster, D. Phil.

	Title:	Vice President Research

	Date:	March 7, 2019

 

SIGNED FOR AND ON BEHALF of

PROMIS NEUROSCIENCES, INC. 

by its authorized signatory:

/s/ Elliot Goldstein

	Name:	Elliot Goldstein, MD

	Title:	President & CEO

	Date:	April 15, 2019

 

 

[signature page]

     

     

    

 

Acknowledged by

/s/ Neil Cashman

Dr. Neil Cashman

Principal Investigator

Department of Neurology

Date: March 8, 2019

 

 

[acknowledgement page]Exhibit 10.3.4

 

Certain identified information has been
excluded from the exhibit pursuant to Item 601(a)(6) of Regulation S-K or pursuant to Item 601(b)(10)(iv) because it is both not material
and is the type of information that the registrant treats as private or confidential. Redacted information is indicated by: [***]

 

 

UBC File: F16-05805

 

September 9, 2019

  

VIA EMAIL

 

Dr. Elliot Goldstein

President and CEO

ProMis Neurosciences, Inc.

Suite 200, 1920 Yonge Street

Toronto, ON

M4S 3E2

[***]

 

Dear Dr. Goldstein,

 

		Re:	Collaborative Research Agreement between The University of British Columbia (“UBC”)
and Vancouver Coastal Health Authority (“Hospital”) (UBC and Hospital collectively, the “Institution”) and ProMis
Neurosciences, Inc. (the “Sponsor”) effective April 1, 2016 and amended by Amendment No. 1 dated December 13, 2017, Amendment
No.2 dated July 5, 2018 and Amendment No.3 dated February 13, 2019 (the “Agreement”)

 

Amendment No. 4

 

The Institution and Sponsor have executed
the Agreement and hereby agree to amend the Agreement as follows:

 

Article 4.1 shall be revised and read as follows:

 

“4,1The
Parties understand and agree that, subject to Article 4.3, and excluding any intellectual property related costs under Section 7, the
total costs to the Sponsor hereunder will be $[***] (Canadian funds). The Parties acknowledge that
any budget categories that may be described in the Project are estimates only and that changes from category to category may be made at
the Institution’s discretion, The Sponsor will pay to UBC the amounts of the following due dates:

 

		1.	Amount already received by UBC		$[***]

 

		2.	Amount due upon signature of this Amendment No. 4	 	$[***]

 

     

     

    

 

		3.	December 1, 2019		$[***]

 

		4.	March 1, 2020	 	$[***]

 

		5.	June 1, 2020	 	$[***]

 

		6.	September 1, 2020	 	$[***]

 

		7.	December 1, 2020	 	$[***]

 

		8.	March 1, 2021	 	$[***]

 

		9.	June 1, 2021	 	$[***]

 

		10.	September 1, 2021	 	$[***]

 

		11.	December 1, 2021	 	$[***]

 

The Sponsor may make payments by wire transfer
to:

 

Pay Via: [***]

 

Pay to: [***]

 

Account number for Canadian dollars: [***]

 

Beneficiary: The University of British Columbia

 

Payment Details: [***]

 

UBC reserves the right to suspend work on all
Projects or to terminate all Projects and this Agreement by delivering written notice of same to the Sponsor if the Sponsor fails to pay
any invoiced amount within 30 calendar days from the due date.

 

The Sponsor will pay interest on all amounts owing
to UBC but not paid on the due date, at the rate of [***]% per annum, calculated annually not in advance. The interest accrues on the
balance of unpaid amounts from time to time outstanding, from the date on which portions of the amounts become due and owing until payment
in full.

 

All other terms and conditions of the Agreement
will remain in full force and effect and will continue for the duration of the Agreement. The Agreement and this Amendment No. 4 will
be read together and constitute one agreement.

 

This Amendment to the Agreement may be signed
in counterparts either through original copies or by facsimile or electronically each of which will be deemed an original and all of which
will constitute the same instrument.

 

(signature page follows)

 

    2 

     

    

 

	
    SIGNED FOR AND ON BEHALF of

    THE UNIVERSITY OF BRITISH COLUMBIA

    by its authorized signatory:

    

	 
	Name:	/s/	 
	Title:	 	 
	Date:	 	 
	 	 	 
	SIGNED FOR AND ON BEHALF of

THE UNIVERSITY OF BRITISH COLUMBIA

by its authorized signatory:

 

	 	 	 
	Name:	/s/	 
	Title:	 	 
	Date:	 	 
	 	 	 
	SIGNED FOR AND ON BEHALF of

VANCOUVER COASTAL HEALTH AUTHORITY

by its authorized signatory:

	 	 	 
	 	 	 
	Name:	/s/	 
	Title:	 	 
	Date:	 	 
	 	 
	SIGNED FOR AND ON BEHALF of

PROMIS NEUROSCIENCES, INC.

by its authorized signatory:

	 	 	 
	/s/ Elliot Goldstein	 
	Name:	Elliot Goldstein, MD	 
	Title:	President & CEO	 
	Date:	Oct. 7 2019	 

 

    Signature Page - 1 

     

    

 

	
    Acknowledged
by
	 

	 	 
	 	 
	
    Dr. Neil Cashman

    Principal Investigator

    Department of
    Neurology

    Date:
	 

 

    Signature Page - 2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00345-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00345-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00345-of-00352.parquet"}]]